Edition:
India

Intercept Pharmaceuticals Inc (ICPT.OQ)

ICPT.OQ on NASDAQ Stock Exchange Global Select Market

61.16USD
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
$61.16
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
292,285
52-wk High
$135.59
52-wk Low
$51.11

Select another date:

Sat, Feb 17 2018

BRIEF-Intercept Pharma Says Sumitomo Dainippon Pharma Enters Into Amendment To Certain License Agreement

* INTERCEPT PHARMA SAYS ON FEB 13, CO, SUMITOMO DAINIPPON PHARMA ENTERED INTO AMENDMENT TO CERTAIN LICENSE AGREEMENT DATED AS OF MARCH 29, 2011

BRIEF-Intercept Pharmaceuticals Reports Q4 Net Loss Per Common & Potential Common Share $4.43

* INTERCEPT PHARMACEUTICALS REPORTS FULL YEAR AND FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Intercept Announces Updated U.S. Prescribing Information For Ocaliva

* INTERCEPT ANNOUNCES UPDATED U.S. PRESCRIBING INFORMATION FOR OCALIVA® (OBETICHOLIC ACID) TO REINFORCE APPROPRIATE DOSING IN PBC PATIENTS WITH ADVANCED CIRRHOSIS

BRIEF-Intercept Pharma Says Shifting Guidance For Announcement Of Phase 3 Reverse Trial In Nash Patients With Compensated Cirrhosis To Q1 2018

* INTERCEPT PHARMA SAYS SHIFTING GUIDANCE FOR ANNOUNCEMENT OF PHASE 3 REVERSE TRIAL IN NASH PATIENTS WITH COMPENSATED CIRRHOSIS TO Q1 2018 - SEC FILING Source text: (http://bit.ly/2CgH2Og) Further company coverage:

BRIEF-Intercept Pharma reports qtrly ‍revenue $41.3 mln vs $5.2 million​

* Intercept Pharmaceuticals reports third quarter 2017 financial results and provides business update

BRIEF-Intercept Pharma posts positive results from Phase 2 AESOP trial

* Intercept announces positive results from Phase 2 AESOP trial evaluating OCA for the treatment of patients with primary sclerosing cholangitis at The Liver Meeting 2017

Intercept does not expect restrictive boxed warning for liver drug

Intercept Pharmaceuticals Inc said on Monday its liver drug, Ocaliva, could carry a boxed warning to help ensure proper dosing but the drugmaker also said it does not expect the updated labeling to be restrictive, sending its shares higher.

BRIEF-Intercept Pharmaceuticals comments on Ocaliva safety and dosing in liver disease patients​

* Intercept Pharmaceuticals Inc comments on Ocaliva (obeticholic acid) safety and dosing in primary biliary cholangitis (PBC) patients​

FDA warns of death, liver injury risks from Intercept's drug

The U.S. Food and Drug Administration (FDA) warned on Thursday that Intercept Pharmaceuticals Inc's drug Ocaliva was being incorrectly dosed in some patients with a rare liver disease, increasing the risk of liver injury and death.

Select another date: